Results 191 to 200 of about 438,635 (219)

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

A Review of Shape Memory Polymers and Composites: Mechanisms, Materials, and Applications

Advanced Materials, 2021
Jinsong Leng, Fenghua Zhang, Yanju Liu
exaly  

Home - About - Disclaimer - Privacy